What does Dr Evgenia Papakrivopoulou Nefro do?

Dr Evgenia Papakrivopoulou Nefro is a specialist medical practice in Etterbeek. Private Limited, started on 28 January 2021, 1 establishment.

What is the address of Dr Evgenia Papakrivopoulou Nefro?

The registered office of Dr Evgenia Papakrivopoulou Nefro is located at Gérardstraat 31, 1040 Etterbeek.

Is Dr Evgenia Papakrivopoulou Nefro still active?

Yes. According to the CBE (3 October 2026) Dr Evgenia Papakrivopoulou Nefro is active, legal situation “Normale toestand”, started on 28 January 2021.

Is Dr Evgenia Papakrivopoulou Nefro registered on Peppol?

Yes, Dr Evgenia Papakrivopoulou Nefro is registered on the Peppol network with ID 0208:0762615285.

What is the enterprise number of Dr Evgenia Papakrivopoulou Nefro?

The enterprise number of Dr Evgenia Papakrivopoulou Nefro is BE0762615285.

When was Dr Evgenia Papakrivopoulou Nefro founded?

Dr Evgenia Papakrivopoulou Nefro was founded on 28 January 2021.

Is Dr Evgenia Papakrivopoulou Nefro a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 28 January 2021; 5 annual accounts filed, latest fiscal year 2025.

How much profit did Dr Evgenia Papakrivopoulou Nefro make in 2025?

Dr Evgenia Papakrivopoulou Nefro posted a profit after taxes of € 262,883 in financial year 2025.

What is the revenue of Dr Evgenia Papakrivopoulou Nefro?

As a small company, Dr Evgenia Papakrivopoulou Nefro is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 366,873.

Dr Evgenia Papakrivopoulou Nefro (Private Limited)

Dossier Dr Evgenia Papakrivopoulou Nefro, printed on 3 October 2026 from databakkes.be/en/0762615285/dr-evgenia-papakrivopoulou-nefro. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 18 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

Dr Evgenia Papakrivopoulou Nefro from Etterbeek, company number BE0762615285, closed financial year 2025 with a result of € 262,883 after tax. For that financial year Dr Evgenia Papakrivopoulou Nefro recorded a gross margin of € 366,873 and equity of € 430,649. Compared with financial year 2024, the result moved from € 236,976 to € 262,883. Profitable, and profit is growing. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 29, 2026.

What it is worth Healthy

€ 430,649

▼ 36% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 262,883

▲ 11% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 107,310

▼ 8% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 500,000 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Wage cost

€ 9,583

▼ 18% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 4,614

▼ 54% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 3,869

▲ € 3,155 vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 156,018

▲ 38% vs 2024

Taxes, VAT and social contributions still to pay.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 269,090 Gross margin 2022: € 269,090 First fiscal year in the series	€ 348,354 Gross margin 2023: € 348,354 ▲ 29% vs 2022 (€ 269,090) Favourable step	€ 328,873 Gross margin 2024: € 328,873 ▼ 6% vs 2023 (€ 348,354) Unfavourable step	€ 366,873 Gross margin 2025: € 366,873 ▲ 12% vs 2024 (€ 328,873) Favourable step	▲ 12%
Profit after taxes	€ 199,896 Profit after taxes 2022: € 199,896 First fiscal year in the series	€ 255,924 Profit after taxes 2023: € 255,924 ▲ 28% vs 2022 (€ 199,896) Favourable step	€ 236,976 Profit after taxes 2024: € 236,976 ▼ 7% vs 2023 (€ 255,924) Unfavourable step	€ 262,883 Profit after taxes 2025: € 262,883 ▲ 11% vs 2024 (€ 236,976) Favourable step	▲ 11%
Equity	€ 421,026 Equity 2022: € 421,026 First fiscal year in the series	€ 676,949 Equity 2023: € 676,949 ▲ 61% vs 2022 (€ 421,026) Favourable step	€ 667,767 Equity 2024: € 667,767 ▼ 1% vs 2023 (€ 676,949) Unfavourable step	€ 430,649 Equity 2025: € 430,649 ▼ 36% vs 2024 (€ 667,767) Unfavourable step	▼ 36%
Total debts	€ 114,203 Total debts 2022: € 114,203 First fiscal year in the series	€ 161,312 Total debts 2023: € 161,312 ▲ 41% vs 2022 (€ 114,203) Unfavourable step	€ 113,387 Total debts 2024: € 113,387 ▼ 30% vs 2023 (€ 161,312) Favourable step	€ 592,526 Total debts 2025: € 592,526 ▲ € 479,139 vs 2024 (€ 113,387) Unfavourable step	▲ € 479,139
Cash	€ 110,193 Cash 2022: € 110,193 First fiscal year in the series	€ 168,685 Cash 2023: € 168,685 ▲ 53% vs 2022 (€ 110,193) Favourable step	€ 116,389 Cash 2024: € 116,389 ▼ 31% vs 2023 (€ 168,685) Unfavourable step	€ 107,310 Cash 2025: € 107,310 ▼ 8% vs 2024 (€ 116,389) Unfavourable step	▼ 8%
Land & buildings	€ 10,087 Land & buildings 2022: € 10,087 First fiscal year in the series	€ 20,120 Land & buildings 2023: € 20,120 ▲ 99% vs 2022 (€ 10,087) Unchanged	€ 17,349 Land & buildings 2024: € 17,349 ▼ 14% vs 2023 (€ 20,120) Unchanged	€ 42,540 Land & buildings 2025: € 42,540 ▲ 145% vs 2024 (€ 17,349) Unchanged	▲ 145%
Retained profit	€ 420,026 Retained profit 2022: € 420,026 First fiscal year in the series	€ 675,949 Retained profit 2023: € 675,949 ▲ 61% vs 2022 (€ 420,026) Favourable step	€ 666,767 Retained profit 2024: € 666,767 ▼ 1% vs 2023 (€ 675,949) Unfavourable step	€ 429,649 Retained profit 2025: € 429,649 ▼ 36% vs 2024 (€ 666,767) Unfavourable step	▼ 36%
Dividend	€ 800 Dividend 2022: € 800 First fiscal year in the series	€ 0 Dividend 2023: € 0 ▼ 100% vs 2022 (€ 800) Unchanged	€ 246,159 Dividend 2024: € 246,159 Unchanged (€ 0) Unchanged	€ 500,000 Dividend 2025: € 500,000 ▲ 103% vs 2024 (€ 246,159) Unchanged	▲ 103%
Balance sheet total	€ 535,229 Balance sheet total 2022: € 535,229 First fiscal year in the series	€ 838,261 Balance sheet total 2023: € 838,261 ▲ 57% vs 2022 (€ 535,229) Unchanged	€ 781,153 Balance sheet total 2024: € 781,153 ▼ 7% vs 2023 (€ 838,261) Unchanged	€ 1,023,175 Balance sheet total 2025: € 1,023,175 ▲ 31% vs 2024 (€ 781,153) Unchanged	▲ 31%

Key figures of Dr Evgenia Papakrivopoulou Nefro, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Dr Evgenia Papakrivopoulou Nefro?

What happened at Dr Evgenia Papakrivopoulou Nefro in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 29, 2026 New annual accounts for financial year 2025: profit of € 262,883 (▲ 11% vs 2024). filed late Source: NBB ↗
Jan 28, 2021 New establishment in Etterbeek. KBO
Jan 28, 2021 Start of the company according to the CBE. KBO

In short

From € 199,896 profit in 2022 to € 262,883 profit in 2025.

Paid € 309,569 in corporate taxes since 2022.

Best year ever: 2025, with € 262,883 profit.

Paid out € 746,959 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at Dr Evgenia Papakrivopoulou Nefro? We notify you, reason included.

Follow Dr Evgenia Papakrivopoulou Nefro

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Establishments

Establishment units

Physical locations of this company

Registered office

Gérardstraat 31

1040 Etterbeek

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0762.615.285

VAT number

BE 0762.615.285

Registered office

Gérardstraat 31, 1040 Etterbeek

Names & denominations

Dr Evgenia Papakrivopoulou Nefro

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

28 January 2021

Peppol

Active · Active since 8 Dec 2025

Activities · NACE

Activiteiten van medisch specialisten

Overige vormen van onderwijs

View on CBE Public ↗ Annual accounts (NBB) ↗